Pharma Pulse 11/6/24: Balancing Personalized Targeting with Protecting Consumers, What Do SMA Caregivers Want? & more
The latest news for pharma industry insiders.
Balancing Personalized Targeting with Protecting Consumer Privacy
Ted Sweetser, VP, Ad Partnerships and Strategy, PurpleLab discusses the need to balance personalized targeting with the ethical imperative to protect consumer privacy.
In a response to a survey, caregivers of people with spinal muscular atrophy identified the risk of severe adverse events and the need for permanent ventilation as the most important factors in treatment decisions. Access to treatment, including cost and availability, ranked third.
From A.I. to Musk’s Brain Chips, the F.D.A.’s Device Unit Faces Rapid Change
The new director overseeing medical devices will confront criticisms about hasty approvals as she ushers in revolutionary technology.
NJ Bio, Inc. and Charles River Laboratories, Inc. announced a strategic alliance to offer complementary services to clients including early development and optimization to manufacturing of antibody drug conjugates (ADCs).
Our Chief Commercial Officer,Delphine Perridy Boile, recently spoke with Pharmaceutical Commerce Magazine about the rapid evolution in pharma driven by unserved patient needs, new technologies, and AI in drug discovery.
She highlights the importance of precise temperature control and customized logistics, especially for biologics and personalized medicines, as the industry adapts to bring innovative treatments to patients faster.
Read the full interview below for more insights on the future of pharma cold chain and sustainability.
#Envirotainer #PharmaInnovation #ColdChainLogistics
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs
